

HEMATOLOGY DISEASE SITE COMMITTEE

CHELSEA HOTEL, TORONTO, ON ROOM: Mountbatten B

MAY 5, 2024 8:00 AM - 12:00 PM

CO-CHAIRS : ANTHONY REIMAN, SARIT ASSOULINE SENIOR INVESTIGATORS: ANNETTE HAY, LOIS SHEPHERD

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To identify and address, through clinical trial and translational research, the disease burden associated with hematologic malignancies in Canada
- To identify clinical trial research opportunities in hematologic malignancies within the Canadian Cancer Trials Group
- To integrate current knowledge regarding therapeutics and tumour biology in hematologic malignancies in trial concept development and conduct
- To integrate and apply new clinical trial methodologies in hematologic malignancies in the Canadian Cancer Trials Group research agenda
- To identify mentoring opportunities for new investigators.

8:00 am	Welcome	Sarit Assouline	
8:05 am	Year's Accomplishments	Anthony Reiman	
8:20 am	Clinical Trials Inspiration and Progress in CLL	Deborah Stephens	
9:20 am	Studies Open/Soon to Open		
	MY.13 MYC.2 LY.17 LY.18	Hira Mian Christopher Venner John Kuruvilla Diego Villa	
10:00 am	Break		
10:15 am	Studies Open/Soon to Open continued		
	HD.11 HD.12 IND.244 CLC.3 SC.26 myeloMATCH suite	Kerry Savage Michael Crump Jean-Francois Larouche, Anca Prica Versha Banerji Pierre Villeneuve Lynn Savoie, Sarit Assouline	



CCTG is a CCS national program.

11:15 am Future Directions/Working Group Reports

	Myeloma	Anthony Reiman
	Lymphoma	John Kuruvilla, Diego Villa, Laurie Sehn
	Leukemia	Lynn Savoie, Sarit Assouline
	Correlative Sciences	Laurie Sehn, Lois Shepherd
11:55 am	Closing Remarks	Anthony Reiman, Sarit Assouline

12:00 pm Meeting Adjourned



CCTG is a CCS national program.